Sponsor oversight without waiting for CRO status decks.

See CRO actions, site risks, amendment impact, safety context, and inspection evidence while the study is changing, not after the next status package arrives.

Discuss Sponsor oversight Compare CRO delivery

Oversight

Sponsor control should not depend on rebuilt status history.

Clinical leadership, QA, regulatory, vendor management, and medical leadership need to see what changed, who acted, and which trial context changed the risk.

Portfolio signal

Enrollment, deviations, query pressure, site risk, document gaps, safety context, and amendment impact remain visible by study, country, and Site.

Vendor accountability

Separate CRO execution, vendor-system source, Sponsor review, and Sponsor acceptance without rebuilding history from slides.

Board and agency question

What changed in the last 72 hours? Which actions are CRO execution versus Sponsor acceptance? Which Sites carry inspection exposure?

Inspection evidence

Answer the inspector from the live study record.

Sponsor inspection readiness depends on live protocol, consent, IRB/EC, deviation, SAE, eTMF, signature, access, and audit evidence. The answer should not require a war room before it exists.

Protocol and consent trace

Current Protocol Version, IRB/EC approval, informed-consent version, Site effectiveness, and subject trace stay connected.

Deviation and SAE trail

Audit trails expose what changed, who acted, why, and which source evidence or medical review supported the decision.

Inspector test

Can an inspector pull protocol, IRB approval, consent trace, deviations, and audit trail without waiting for a rebuilt package?

Connected systems

Sponsor oversight spans the stack.

Sponsor visibility usually crosses CTMS, eTMF, EDC, RTSM, identity, learning, safety, labs, Site source, and reporting systems. Clinistack turns those signals into reviewable work with owner, source, and acceptance state intact.

CRO and vendor work

Monitor findings, activation blockers, source-data mismatches, document gaps, and safety reviews retain owner, source, and disposition.

Board and agency readiness

Clinical leaders can connect enrollment, amendments, safety context, inspection exposure, and vendor performance before a board or agency meeting.

Sponsor acceptance question

Which source system changed? Which action is pending Sponsor review? Which evidence explains the current risk state?

First rollout

Bring the study question your team keeps rebuilding.

We will review the product path, system context, owners, evidence, and rollout approach that fit the trial work in front of you.

Discuss your trial setup